Author’s response to reviews

Title: Evaluation of scoring systems without endoscopic findings for predicting outcomes in patients with upper gastrointestinal bleeding

Authors:

Il-Gyu Ko (rhdlfrb@naver.com)

Sung-Eun Kim (happytime3@hanmail.net)

Bok Soon Chang (meerachang@khnmc.or.kr)

Min Seob Kwak (Kwac63@khnmc.or.kr)

Jin Young Yoon (htherehthere@gmail.com)

Jae Myung Cha (clicknox@khnmc.or.kr)

Hyun Phil Shin (megadoctor@khnmc.or.kr)

Joung Il Lee (jilee7@khnmc.or.kr)

Sang Hyun Kim (ssan77@naver.com)

Jin Hee Han (esthesi@naver.com)

Jung Won Jeon (drglory@naver.com)

Version: 3 Date: 16 Oct 2017

Author’s response to reviews:

Answers to Editor Comments

Manuscript title: Evaluation of scoring systems without endoscopic findings for predicting outcomes in patients with upper gastrointestinal bleeding

Authors: IL-Gyu Ko, Sung-Eun Kim, Bok Soon Chang, Min Seob Kwak, Jin Young Yoon, Jae Myung Cha, Hyun Phil Shin, Joung Il Lee, Sang Hyun Kim, Jin Hee Han, Jung Won Jeon

Article type: Original Research

We sincerely appreciate for your kind advice and comments to our manuscript. We revised the manuscript as editor comments. We represent the specific modifications in response to the comments by red-letters in our manuscript.
Editor Comments:

There is an important error in the definition of high dose PPI in your revised manuscript, please revise your description again (high dose or non-high dose) after referring to some papers (Ann Intern Med 2010;152:101; Arch Int Med 2010;170:751; JAMA Intern Med 2014; 174: 1755–62; Gut 2011;60:1170; N Engl J Med 2007; 356:1631) please take care of it, it is your last change to revise Good luck to you.

Author answer

We fully referenced the paper you presented. As you pointed out, there are some mistakes in our paper. We would modify the statement according to your advice. Finally, we will consider your suggestion in the further study. We hope this answer will satisfy you.

Following sentence were corrected to the method part

The high dose proton pump inhibitor (Pantoloc® Takeda GmbH, Singen, Germany, 80 mg bolus once then 40mg every 6 hours) was administered to all subjects with UGIB intravenously. (Line 2-3 of page 7)